Inhaled NAC in Treatment of IPF

Withdrawn before enrolling · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Idiopathic Pulmonary Fibrosis (IPF)

In brief

This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis. The study will also create a bank of data, blood, and sputum from IPF patients for future research.

Key facts

Study ID

NCT03720483

Run by

University of Colorado, Denver

People needed

0

Starts

2022-01-01

Expected to finish

2023-12-01

Last updated by the study team

2021-06-08

Who can join

Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed by study team with expertise in IPF utilizing standard ATS/ERS definition of "probable" or "definite" IPF
• DLCO >50% predicted
• FVC >60% predicted
• FEV1/FVC > 0.7

You may not qualify if…

• History of bronchospasm (requiring treatment)
• Current acute exacerbation of their IPF disease
• Current smoker
• Supplemental O2 requirement > 4 liters/min via nasal cannula
• History of asthma, COPD, coronary artery disease, or cancer
• Currently using NAC, hypertonic saline, or DNase (dornase alfa) inhalation therapy

Where it is running

• University of Colorado Anschutz Medical Campus — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.